皮肤念珠菌病,由白色念珠菌引起,是一种严重而令人沮丧的情况,找到有效的治疗方法可能很有挑战性。因此,法尼醇纳米粒子的开发是一个令人兴奋的突破。乙醇体是一种新型的经皮药物递送载体,将一定浓度(10-45%)的醇掺入脂质囊泡中,与常规脂质体相比,导致改善的渗透性和包封率。法尼醇是一种群体感应分子,参与白色念珠菌的形态发生调节,这些醇质体为治疗这种常见的真菌感染提供了一种有希望的新方法。本研究开发了载有法尼醇的醇质体(法尼醇-醇质体)的制剂,并评估了在体外和体内治疗白色念珠菌引起的皮肤念珠菌病的应用。通过乙醇注射方法成功开发了法尼醇-醇质体。法尼醇-醇质体的治疗特性,如颗粒大小,zeta电位,和形态学,很好的特点。根据结果,法尼醇-乙醇体对白色念珠菌细胞生长和生物膜形成的抑制作用增强。在动物感染模型中,通过透皮给药治疗法尼醇-醇质体可有效缓解皮肤念珠菌病引起的症状,并减少真菌的数量。我们还观察到醇质体在体外和体内显着增强了药物递送功效。这些结果表明,法尼醇-醇质体可以在治疗皮肤念珠菌病中提供未来有希望的作用。
目的:由念珠菌感染引起的皮肤念珠菌病是影响所有年龄组个体的普遍病症。作为一种微生物群落,生物膜对宿主感染有益,并减轻抗真菌治疗的临床效果。在白色念珠菌中,法尼醇通过调节多种信号通路有效地抑制了酵母到菌丝的转变和生物膜的形成。然而,法尼醇的特性,如疏水性,波动性,降解性,在各种条件下的不稳定性会限制其有效性。纳米技术具有提高该分子的效率和利用率的潜力。在小鼠皮肤念珠菌病的感染模型中,通过经皮给药法呢醇-醇质体的治疗表现出非常显著的对白色念珠菌的治疗效果。许多患有真菌性皮肤感染的患者将从这项研究中受益。
Cutaneous candidiasis, caused by Candida albicans, is a severe and frustrating condition, and finding effective treatments can be challenging. Therefore, the development of farnesol-loaded nanoparticles is an exciting breakthrough.
Ethosomes are a novel transdermal drug delivery carrier that incorporates a certain concentration (10-45%) of alcohols into lipid vesicles, resulting in improved permeability and encapsulation rates compared to conventional liposomes. Farnesol is a quorum-sensing molecule involved in morphogenesis regulation in C. albicans, and these ethosomes offer a promising new approach to treating this common fungal infection. This study develops the formulation of farnesol-loaded
ethosomes (farnesol-
ethosomes) and assesses applications in treating cutaneous candidiasis induced by C. albicans in vitro and in vivo. Farnesol-
ethosomes were successfully developed by ethanol injection method. Therapeutic properties of farnesol-
ethosomes, such as particle size, zeta potential, and morphology, were well characterized. According to the results, farnesol-ethosomes demonstrated an increased inhibition effect on cells\' growth and biofilm formation in C. albicans. In Animal infection models, treating farnesol-ethosomes by transdermal administration effectively relieved symptoms caused by cutaneous candidiasis and reduced fungal burdens in quantity. We also observed that
ethosomes significantly enhanced drug delivery efficacy in vitro and in vivo. These results indicate that farnesol-ethosomes can provide future promising roles in curing cutaneous candidiasis.
OBJECTIVE: Cutaneous candidiasis attributed to Candida infection is a prevalent condition that impacts individuals of all age groups. As a type of microbial community, biofilms confer benefits to host infections and mitigate the clinical effects of antifungal treatments. In C. albicans, the yeast-to-hypha transition and biofilm formation are effectively suppressed by farnesol through its modulation of multiple signaling pathway. However, the characteristics of farnesol such as hydrophobicity, volatility, degradability, and instability in various conditions can impose limitations on its effectiveness. Nanotechnology holds the potential to enhance the efficiency and utilization of this molecule. Treatment of farnesol-ethosomes by transdermal administration demonstrated a very remarkable therapeutic effect against C. albicans in infection model of cutaneous candidiasis in mice. Many patients suffering fungal skin infection will benefit from this study.